Our biotech company developed and adapted to High Throughput Screening, a new family of biological assays
capable to quantify simultaneously clot formation and clot lysis (HemostaBioplatformScreen), total antioxidant capacity (OxidantBioplatformScreen) and low-density lipoprotein modification (AtheroBioplatformScreen).
With these proven proprietary new HTS Platforms named as BioPlatformScreen
, the biotech group are creating a continuously novel and promising pipeline of drug candidates.
Main relevant characteristics of BioPlatformScreen are:
1. No interferences with biological matrix.
2. Capable to evaluate pathways instead of single targets rendering simultaneously multiple HITS for different targets.
3. High value biological information.
4. Provide efficient screening tools to therapeutic areas classically deprived of HTS.
Coagulation (pro and anti)
Fibrinolysis (pro and anti)
Antiatherosclerotic (LDL peroxidation inhibitors)
5. Ex vivo information useful to drive successfully clinical trials (Phase I, Phase II and Phase III).
6. Screening Capacity over 10 million compounds per year (HTS Center fully operative).
Don't hesitate to take this advantageous service.